FDA Neuroscience Director Dunn's Appearance At Tanezumab AdComm Confirms Neurology Office Is Intact

 
• By Ramsey Baghdadi

Dunn’s participation at the panel meeting ended speculation that he left the US FDA.  

Dunn Will By Key A Figure In Alzheimer's Drug Review

More from US FDA

More from Agency Leadership